Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-16
2011-12-06
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S568000, C514S734000
Reexamination Certificate
active
08071641
ABSTRACT:
Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
REFERENCES:
patent: 4371720 (1983-02-01), Johnson et al.
patent: 5013387 (1991-05-01), Goodwin et al.
patent: 5081122 (1992-01-01), Ward
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5461034 (1995-10-01), Rodan et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6403123 (2002-06-01), Scott et al.
patent: 6410588 (2002-06-01), Feldmann et al.
patent: 6531636 (2003-03-01), Mechoulam et al.
patent: 7071231 (2006-07-01), Spevak et al.
patent: 0444451 (1991-04-01), None
patent: 0570920 (1993-11-01), None
patent: 2735774 (1997-09-01), None
patent: WO 94/12466 (1994-06-01), None
patent: WO 94/12466 (1994-09-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 99/53917 (1999-10-01), None
patent: WO 00/19773 (2000-06-01), None
patent: WO 02/13814 (2002-02-01), None
patent: WO 03/063847 (2003-07-01), None
Gorter Cancer cachexia and cannabinoids. Forschende Komplementarmedizin, 1999 vol. 6, No. Suppl. 3, pp. 21-22. ISSN: 1021-7096.
Communication Pursuant to Article 94(3) EPC Dated Dec. 18, 2009 From the European Patent Office Re.: Application No. 05703237.7.
International Search Report and the Written Opinion Dated Jun. 21, 2005 From the International Searching Authority Re.: Application No. PCT/IL2005/000196.
Office Action Dated Feb. 1, 2010 From the Israel Patent Office Re.: Application No. 160420 and Its Translation Into English.
Official Action Dated Feb. 16, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/589,623.
Adis “Cannabis-Based Medicines—GW Pharmaceuticals. High CBD, High THC, Medicinal Cannabis—GW Pharmaceuticals, THC:CBD”, Drugs R & D, 4(5): 306-309, 2003.
Adams et al. “Isolation of Cannabinol, Cannabidiol and Quebrachitol From Red Oil of Minnesota Wild Hemp”, Journal of the American Chemical Society, 62: 2194-2196, 1940.
Burstein et al. “Synthetic Nonpsychotropic Cannabinoids With Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities”, Journal of Medicinal Chemistry, 35: 3135-3141, 1992.
Coffey et al. “Tetrahydrocannabinol Inhibition of Macrophage Nitric Oxide Production”, Biochemical Pharmacology, 52: 743-751, 1996.
Devane et al. “Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor”, Science, 258: 1946-1949, 1992.
Edery et al. “Structural Requirements for Cannabinoid Activity”, Annals of the NY Academy of Sciences, 191: 40-53, 1971.
Felder et al. “Anandamide, An Endogenous Cannabimimetic Eicosanoid, Binds to the Cloned Human Cannabinoid Receptor and Stimulates Receptor-Mediated Signal Transduction”, Proc. Natl. Acad. Sci. USA, 90: 7656-7660, 1993.
Gaoni et al. “The Isolation and Structure of Δ1—Tetrahydrocannabinol and Other Neutral Cannbinoids From Hashish”, Journal of the American Chemical Society, 93: 217-224, 1971.
Hanu{hacek over (s)} et al. “Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor”, Journal of Medicinal Chemistry, 36: 3032-3034, 1993.
Hanu{hacek over (s)} et al. “2-Arachidonyl Glyceryl Ether, An Endogenous Agonsit of the Cannabinoid CBI Receptor”, Proc. Natl. Acad. Sci. USA, 98(7): 3662-3665, 2001.
Houry et al. “Benzoxocin and Bensoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity. A Correction”, Journal of Medicinal Chemistry, 18(9): 951-952, 1975.
Zuardi et al. “Antipsychotic Effect of Cannabidiol”, Journal of Clinical Psychiatry, 56(10): 485-486, 1995.
Formukong et al. “Analgesic and Antiflammatory Activity of Constituents of Cannabis Sativa L.”, Inflammation, 12(4): 361-371, 1988.
Venstrom et al. “Survival After Pancreas Transplantation in Patients With Diabetes and Preserved Kidney Function”, JAMA, 290(21): 2817-2823, 2003. Correction: 291(13); 1566, 2004.
Kendall et al. “Pancreas and Islet Transplantation”, The Endocrinologist, 5: 28-35, 1995.
Mechoulam “Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects”, Academic Press, 65: Book Info & Table of Contents, 1973.
Houry et al. “Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity”, Journal of Medicinal Chemistry, 17(3): 287-293, 1974.
Mechoulam et al. “Hashish—I. The Structure of Cannabidiol”, Tetrahedron, 19: 2073-2078, 1963.
Mechoulam et al. “Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors”, Biochemical Pharmacology, 50(1): 83-90, 1995.
Mechoulam et al. “Recent Advances in the Chemistry and Biochemistry of Cannabis”, Chemical Reviews, 76(1): 75-112, 1976.
Mechoulam et al. “Synthesis and Biological Activity of Five Tetrahydrocannabinol Metabolites”, Journal of the American Chemical Society, 94(22): 7930-7931, 1972.
Mechoulam et al. “Stereochemical Requirements for Cannabinoid Activity”, Journal of Medicinal Chemistry, 23(10): 1068-1072, 1980.
Mechoulam et al. “Chemical Basis of Hashish Activity”, Science, 169(3945): 611-612, 1970.
Mechoulam et al. “Synthesis of the Indivivdual, Pharmacologically Distinct, Enantiomers of A Tetrahydrocannabinol Derivative”, Tetrahedron: Asymmetry, 1(5): 315-318, 1990.
Murphy et al. “Cannabinoid Geometry and Biological Activity”, Marijuana/Cannbinoids: Neurobiology and Neurophysiology, p. 1-33, 1992.
Leite et al. “Anticonvulsant Effects of the (−) and (+)Isomers of Cannabidiol and Their Dimethylheptyl Homologs”, Pharmacology, 24: 141-146, 1982.
Zuardi et al. “Effects of Cannabidiol in Animal Models Predictive of Antipsychotic Activity”, Psychopharmacology, 104(2): 260-264, 1991.
Rhee et al. “Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibiton of Adenylylcyclase”, Journal of Medicinal Chemistry, 40: 3228-3233, 1997.
Robertson “Seminars in Medicine of the Beth Israel Hospital, Boston: Pancreatic and Islet Transplantation for Diabetes—Cures of Curiosities?”, The New England Journal of Medicine, 327(26): 1861-1868.
Petrzilka et al. “Synthese und Chiralität des (−)-Cannabidiols”, Helvetica Chimica Acta, 50, Fasciculus 2(73-74/Chap.74): 719-723, 1967.
Sheskin et al. “Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor”, Journal of Mrdicinal Chemistry, 40: 659-667, 1997.
Srebnik et al. “Base-Catalysed Double-Bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects”, Journal of the Chemical Society, Perkin Transactions I, p. 2881-2886, 1984.
Mechoulam et al. “A Total Synthesis of D1-Δ1—Tetrahydrocannabinol, the Active Constituent of Hashish”, Journal of the American Chemical Society, 87(14): 3273-3275, 1965.
Watzl et al. “Influence of Marijuana Components (THC and CBD) on Human Mononuclear Cell Cytokine Secretion in Vitro”, Drugs of Abuse, Immunity, and Immunodeficiency, p. 63-70, 1991.
??? “Cannabis-Based Medicines—GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis—GW Pharmaceuticals, THC: CBD”, Drugs R&D, 4(5): 306-309, 2003. p. 307, 4th Full §.
Weiss et al. “Cytokine Production in Linomide-Treated Nod Mice and the Potential Role of A Th1/Th2 Shift on Autoimmune and Anti-Inflammatory Processes”, Cytokine, 19(2): 85-93, 2002. Fig.1, 4, p. 87-91, § entitled “Discussion”.
Srivastava et al. “Δ9 Tetrahydrocannabinol and Cannabidiol Alter Cytokine Production by Human Immune Cells”, Immunopharmacology,
Gallily Ruth
Mechoulam Raphael
Slavin Shimon
Weiss Lola
Zeira Michael
Hadsit Hadasit Medical Research Services and Development Ltd.
Kim Jennifer M
Yissum Research Development Company of the Hebrew University of
LandOfFree
Treating or preventing diabetes with cannabidiol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating or preventing diabetes with cannabidiol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating or preventing diabetes with cannabidiol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297455